Synthego Stock

Genome Engineering Solutions

Sign up today and learn more about Synthego Stock

Invest in or value your shares in one or many pre-IPO companies through an EquityZen investment vehicle.

Founded

2012

Notable Investors

8VC

Headquarters

Redwood City CA, US

Total Funding

$415M

About Synthego Stock

Synthego is a provider of genome engineering solutions. The company offers CRISPR kits, such as the CRISPR evolution, a portfolio of synthetic RNA designed for CRISPR genome editing and research. Synthego claims that its CRISPR genome engineering technology enables scientists to easily and precisely edit the DNA of any genome. Select applications of gene editing include pathway analysis, stem cells, and diagnostics. The company also offers two products: CRISPR-edited iPS cells and Engineered Cells.

The company is headquartered in Redwood City, CA, and was founded in July 2012. Notable investors include Founders Fund, 8VC, and Menlo Ventures.

Investors

Funding History

June 2013$8.3M
December 2016$4.4M
December 2016$41.9M
October 2018$116M
June 2020$100M
December 2021$144M

Management

Chief Executive Officer

Paul Dabrowski

Chief Financial Officer

Avi Raval

Press

Join 630,000+ Investors and Shareholders

On our trusted digital marketplace for private companies

EquityZen Recognized As:

Logo